Farm Bill, Trump’s Comments, and Cuomo’s Move Make Cannabis Red Hot

HENDERSON, NV / ACCESSWIRE / December 20, 2018 / December has been a big month for cannabis. First, the House and Senate passed the Farm Bill which will make hemp legal federally. Then, Trump commented that he was open to making cannabis legal. Finally, this week Governor of New York, Andrew Cuomo, called for legalizing recreational Marijuana in New York.

The news keeps coming, and cannabis stocks look ready to breakout.

Today we are highlighting: Real Brands, Inc. (RLBD), Canopy Growth Corporation (CGC), CV Sciences, Inc. (OTCQB: CVSI), Aurora Cannabis, Inc. (NYSE: ACB), and Tilray, Inc. (TLRY).

Hemp/CBD beverages could be the biggest winners in the cannabis industry.

Take Real Brands, Inc. (RLBD) (Market Cap: $14.649M, Share Price: $0.13), the company is developing a CBD-infused beverage called Omegahempâ„¢. RLBD has strong management with a solid background in branding and the beverage industry; and plans to expand their holdings focusing on at least three CBD categories: smokables, edibles and topical balms and lotions.

Peter N. Christos, Chairman of Real Brands, Inc. since June 2015, is a Wall Street executive with 30+ years’ experience. He has also been a co-founder in both private and public companies;

The company is very close to its next production run, meaning there could be major news on the way. Now’s the time to research RLBD.

Canopy Growth Corporation (CGC) (Market Cap: $9.716B, Share Price: $28.10) made big news earlier this year receiving investment capital from Constellation Brands and announced recently that it has entered into two agreements with 48North Cannabis Corp. 48North will supply Canopy Growth with dried cannabis produced from high-grade, unique genetics, grown at 48North's wholly-owned facility, DelShen Therapeutics Corp. The total volume of the Supply Agreement is estimated to be a minimum of 1,200 kilograms and deliverable over the course of 12 months.

CV Sciences, Inc. (CVSI) (Market Cap: $441.062M, Share Price: $4.61) just built expansive manufacturing operations, which also house numerous marketing and distribution teams responsible for a growing list of consumer products and marijuana edibles containing plant-based CBD. CV Sciences is helping to secure San Diego as a global hub for the state's cannabis supply chain after the passing of favorable local and federal regulations.

Aurora Cannabis, Inc. (ACB) (Market Cap: $5.305B, Share Price: $5.29) a Canadian marijuana producer, was just selected to supply medical cannabis to Luxembourg. The decision by the Luxembourg Health Ministry helps Aurora expand its footprint in the European Union and comes more than a week after the company announced it completed the first shipment of medical marijuana to the Czech Republic.

Tilray, Inc. (TLRY) (Market Cap: $6.615B, Share Price: $71.00) has been busy recently, investing $5.6 million in Canada-based Rose LifeScience, a producer of cannabis. Also, a wholly-owned subsidiary of Tilray called High Park Farms entered into an exclusive sale, distribution, and market agreement to deliver its Dubon branded cannabis products in the province of Quebec.

Legal Disclaimer:

This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting has agreed to a three-month term consulting agreement with RLBD dated 8/31/18. The agreement calls for $100,000 note issued to Regal Consulting, and 2,500,000 restricted 144 shares of RLBD for three months of service. Regal has elected to convert $73,000 of principal of the $100,000 note into 2,761,872 Restricted 144 shares of RLBD. All payments were made directly by Real Brands, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. RLBD was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.